Hernández Molina J M, Llosá J, Martinez Brocal A, Ventosa A
Servicio de Microbiología, Hospital General Virgen de las Nieves, Granada, Spain.
Mycopathologia. 1992 Apr;118(1):15-21. doi: 10.1007/BF00472565.
The in vitro activity of several new imidazoles, cloconazole, sulconazole, butoconazole, isoconazole and fenticonazole, were compared with those of amphothericin B, flucytosine, and three azoles: econazole, miconazole and ketoconazole against isolates of pathogenic Candida. A total of 186 clinical isolates of 10 species of the genus Candida and two culture collection strains were tested by an agar-dilution technique. Isoconazole was the most active azole, followed by butoconazole sulconazole. Differences between some of the species in their susceptibility to the antifungal agents were noted. Sulconazole and cloconazole had the highest activity in vitro against 106 isolates of C. albicans. Butoconazole and isoconazole were also very active against isolates of C. albicans, and were the most active azole compounds against 80 isolates of Candida spp.
将几种新型咪唑类药物(氯康唑、硫康唑、布康唑、异康唑和芬替康唑)的体外活性与两性霉素B、氟胞嘧啶以及三种唑类药物(益康唑、咪康唑和酮康唑)针对致病性念珠菌分离株的活性进行了比较。采用琼脂稀释技术对总共186株来自念珠菌属10个种的临床分离株以及两株培养保藏菌株进行了测试。异康唑是活性最强的唑类药物,其次是布康唑、硫康唑。注意到某些菌种对抗真菌药物的敏感性存在差异。硫康唑和氯康唑对106株白色念珠菌分离株具有最高的体外活性。布康唑和异康唑对白色念珠菌分离株也具有很高的活性,并且是针对80株念珠菌属分离株活性最强的唑类化合物。